Hepatitis C and HIV: ribavirin plus interferon study recruiting
- PMID: 11365407
Hepatitis C and HIV: ribavirin plus interferon study recruiting
Abstract
AIDS: The first trial study for individuals with both HIV and hepatitis C infections is opening in 14 U.S. cities, sponsored by the American Foundation for AIDS Research (AmFAR) with partial funding from Schering Plough. The random blind trial will assign interferon or interferon alpha-2b plus ribavirin for 48 weeks to 200 volunteers. Adults over 18 years old who are HIV-positive, with hepatitis C, using treatment approved by the Food and Drug Administration (FDA) for a minimum of four weeks, are eligible for the program. There are 29 exclusions for specific medical conditions or medications. The costs of tests and medication beyond ribavirin to treat hepatitis C are the responsibility of the volunteer. Schering Plough's patient assistance program will provide interferon for those who cannot afford it. For more information call AmFAR.
Similar articles
-
Hepatitis C: new treatment overview.AIDS Treat News. 1998 Sep 4;(302):5-6. AIDS Treat News. 1998. PMID: 11365763
-
Hepatitis C important treatment advance: interview with Douglas Dieterich, M.D. Interview by John S. James.AIDS Treat News. 1998 May 15;(No 295):1-5. AIDS Treat News. 1998. PMID: 11365406
-
Ribavirin approved with a big fat price.Notes Undergr. 1998 Sep-Oct;(No 37):10-1. Notes Undergr. 1998. PMID: 11365818
-
HIV and hepatitis C virus coinfection: bad bedfellows.Top HIV Med. 2005 Oct-Nov;13(4):112-6. Top HIV Med. 2005. PMID: 16304454 Review.
-
Treatment of hepatitis C virus/HIV coinfection.Clin Liver Dis. 2005 Aug;9(3):525-33, ix. doi: 10.1016/j.cld.2005.05.008. Clin Liver Dis. 2005. PMID: 16023981 Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Medical
Miscellaneous